PENTABASE A/SAktiv

CVR 30197852Stiftet 2007

Økonomiske nøgletal

10.461.737 kr.+47,4%
Bruttofortjeneste 2025
+15,3%
Gennemsnitlig vækst pr. år 2017–2025
0100 mio.200 mio.300 mio.’17’18’19’20’21’22’23’24’25

Nøgletal

2025
Balancens sammensætning
OmsætningsaktiverAnlægsaktiverGæld og hensatte forpligtelserEgenkapital
0100 mio.200 mio.300 mio.’17’18’19’20’21’22’23’24’25

Udbytte

foreslået
2022

Der er ikke foreslået udbytte for regnskabsåret.

Historik
20220 kr.
2021150.000.000 kr.
2020125.000.000 kr.
20192.700.000 kr.

Foreslået udbytte for regnskabsåret fra årsrapportens resultatdisponering (udbetales normalt året efter generalforsamlingen).

Selskabsskat

Virksomheden er sambeskattet. Skatten opgøres samlet hos administrationsselskabet SCIENT. INVEST ApS.

Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk

Regnskabstal2017–2025
201720182019202020212022202320242025
Balance — aktiver
Likvide beholdninger969.134393.6531.307.83931.218.63720.589.98059.771.99011.397.22110.325.4306.175.187
Omsætningsaktiver i alt2.608.7492.714.5443.549.648185.364.260——54.216.94648.272.47638.192.442
Anlægsaktiver i alt771.841838.7521.082.11216.860.37321.642.47221.222.86920.299.82618.550.87717.081.791
Aktiver i alt3.380.5903.553.2964.631.760202.224.633280.302.08593.371.27874.516.77266.823.35355.274.233
Balance — passiver
Kortfristede gældsforpligtelser1.185.041563.4241.596.09666.915.14866.713.27016.054.51614.805.13512.748.3402.091.649
Langfristede gældsforpligtelser1.035.0001.035.0000—549.7170———
Gældsforpligtelser i alt2.220.0411.598.4241.596.09666.915.14867.262.98716.054.51614.805.13512.748.3402.091.649
Selskabskapital272.483272.483286.483286.4831.145.9321.145.9321.145.9321.145.9321.145.932
Overført resultat888.0661.682.38949.18110.023.00261.466.62176.170.83058.559.95252.929.08152.036.652
Årets resultat877.606794.323507.352144.229.286189.325.9791.300.270-17.605.125-5.636.624-892.430
Egenkapital i alt1.160.5491.954.8723.035.664135.309.485212.612.55377.316.76259.711.63754.075.01353.182.584
Resultatopgørelse
Bruttofortjeneste3.359.6574.368.0294.086.403199.223.890290.002.99751.677.6273.587.8337.095.78910.461.737
Resultat af primær drift902.466855.714562.742184.398.149241.922.726105.144-23.752.983-8.215.706-5.712.008
EBITDA1.110.9421.086.917884.829185.024.663243.823.2064.322.379-21.815.356-6.576.885-4.196.747
Resultat før skat877.606794.323507.352184.356.613241.929.0541.288.414-22.668.606-7.259.170-1.177.610
Årets resultat877.606794.323507.352144.229.286189.325.9791.300.270-17.605.125-5.636.624-892.430
Personaleomkostninger2.248.7153.281.1123.201.57414.199.22746.179.79147.076.79825.403.18913.672.67414.658.484
Af- og nedskrivninger208.476231.203322.087626.5141.900.4804.217.2351.937.6271.638.8211.515.261
Andre nøgletal
Ansatte699258288392324
Udbytte——2.700.000125.000.000150.000.0000———

En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.

Om virksomheden

Årsrapport 2025

PentaBase A/S is a knowledge-driven organization committed to maintaining the highest scientific and ethical standards. We exclusively develop and provide products and services where there is strong clinical evidence supporting the relevance of the underlying biomarkers. Our mission is to advance precision medicine by delivering innovative molecular diagnostic solutions that improve patient stratification, treatment selection, and disease monitoring. Our activities are centered around proprietary DNA technologies and a comprehensive portfolio of molecular diagnostic products supporting the detection, characterization, and monitoring of cancer-related genetic and epigenetic biomarkers. In addition, we collaborate with research institutions, hospitals, and industrial partners by making our proprietary DNA platform technologies available for research and development within molecular diagnostics and life sciences. During 2025, PentaBase continued to strengthen its strategic focus on oncology diagnostics while advancing the commercialization of recently launched technologies and expanding collaborations with international clinical and research partners. Significant efforts have also been dedicated to further developing the Company's proprietary technology platforms and protecting its intellectual property portfolio. Management is satisfied with the Company's development during 2025. The financial performance improved significantly compared with the previous ye

Uddrag af ledelsesberetningen i den seneste årsrapport.

PENTABASE A/S — cvrprofil.dk